January 23, 2019 12:51pm
The opening was about the “feeling” of the oversold but, the reliance of trust versus conviction pushes the session …
The Advance/Decline Line has deteriorated ...
Yet the “bottoms” are being bought!
There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?
Confidence perceived is not always value achieved!
The 6 W’s: Who, what, where, when, why and what of it …
Pre-open post, “the phoenix rises as “some” of the CRISPRs upsurge … While the oversold should flaunt their “stuff” as US futures point to an upbeat open, after Tuesday’s sharp losses.”
The iShares Nasdaq Biotechnology (IBB) indicated a NEGATIVE -0.17% DOWNSIDE which had dipped -1.10% at the mid-day down from -1.79% at the hourly moving.
When the Advance/Decline Line (A/DL) of 45 covered companies:
- The open was positive with the A/DL to 32/10 and 3 flat;
- The first hour dived neutral with an A/DL of 22/22 and 1 flat;
- The 12 pm hour fell dramatically with an A/DL of 10/32 and 3 flats;
- The mid-day stayed negative with an A/DL of 9/34 and 2 flat;
The CRISPERs got “hit” even harder – boy, was I WRONG about an upsurge: CRSP -$2.56 or -7.65% to $30.52, EDIT -$1.32 or -6.25% to $19.70 and NTLA -$0.59 or -4.17% to $13.57 – still trading equities!
The UGLY lead the downside: SAGE (-$7.69 or -5.86%), BLUE (-$8.00 or -6.40%), BMRN (-$2.50 or -2.61% to $02.55), CRSP (-$2.85 or -8.60% to $30.28) and GBT (-$2.21 or -4.62% to $45.01) …
While WEAK … “upsiders”: OSIR (+$0.41 or +2.91% to $14.41), BLFS (+$0.35 or +2.18% to $12.67), ATHX (+$0.16 or +11.37% to $1.54) while MDXG (+$0.09 or +3.27% to $2.80) rebounded
BSTG (-$0.12 or -5.36%) fumbles with questions of its ability and viability to continue as a public company!
PSTI, AGTC and RENE.L remain flat enjoying being “splat” versus a hammering.
I kept talking about uncertainty as many fear trading of the recent lows yet MISSED today.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.